Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $17.2 million.

  • Editas Medicine's Cash from Financing Activities changed N/A to $17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.7 million, marking a year-over-year increase of 755145.91%. This contributed to the annual value of $56.0 million for FY2024, which is 5253.52% down from last year.
  • As of Q3 2025, Editas Medicine's Cash from Financing Activities stood at $17.2 million.
  • In the past 5 years, Editas Medicine's Cash from Financing Activities ranged from a high of $261.5 million in Q1 2021 and a low of -$1.4 million during Q1 2025
  • Its 5-year average for Cash from Financing Activities is $30.0 million, with a median of $838000.0 in 2021.
  • Per our database at Business Quant, Editas Medicine's Cash from Financing Activities skyrocketed by 3192316.08% in 2023 and then crashed by 84843.75% in 2025.
  • Quarter analysis of 5 years shows Editas Medicine's Cash from Financing Activities stood at $1.1 million in 2021, then plummeted by 41.44% to $619000.0 in 2022, then dropped by 16.96% to $514000.0 in 2023, then skyrocketed by 10700.19% to $55.5 million in 2024, then tumbled by 69.07% to $17.2 million in 2025.
  • Its last three reported values are $17.2 million in Q3 2025, $7.4 million for Q2 2025, and -$1.4 million during Q1 2025.